A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Granisetron
Thalidomide
Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Granisetron
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vecuronium.
Granisetron
Suvorexant
Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Granisetron
Sodium oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Vecuronium.
Granisetron
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Vecuronium.
Granisetron
Rotigotine
Vecuronium may increase the sedative activities of Rotigotine.
Granisetron
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Vecuronium.
Granisetron
Paraldehyde
Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Granisetron
Orphenadrine
Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Granisetron
Methotrimeprazine
Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Granisetron
Hydrocodone
Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Mechlorethamine
Oliceridine
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Pancuronium is combined with Oliceridine.
Mechlorethamine
Remimazolam
The risk or severity of sedation can be increased when Remimazolam is combined with Pancuronium.
Mechlorethamine
Magnesium
Pancuronium can cause a decrease in the absorption of Magnesium resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mechlorethamine
Lasmiditan
The risk or severity of adverse effects can be increased when Pancuronium is combined with Lasmiditan.
Mechlorethamine
Cyclobenzaprine
The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pancuronium.
Mechlorethamine
Solriamfetol
The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Pancuronium.
Mechlorethamine
Esketamine
The risk or severity of adverse effects can be increased when Pancuronium is combined with Esketamine.
Mechlorethamine
Macimorelin
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Pancuronium.
Mechlorethamine
Medical Cannabis
The risk or severity of Tachycardia can be increased when Pancuronium is combined with Medical Cannabis.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3